AC IMMUNE ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING
June 28 2017 - 7:40AM
Lausanne, Switzerland, June 28, 2017 - AC Immune
SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical
company focused on neurodegenerative diseases, today announced that
the shareholders of the Company have approved all resolutions as
proposed by the Board of Directors at the Company's Annual General
Meeting which took place today in Lausanne, including:
- The annual report and the financial statements for the year
2016
- The appropriation of loss
- The discharge of the members of the Board of Directors and the
Executive Committee
- The compensation for the members of the Board of Directors and
the Executive Committee
- The re-election of the Members of the Board and the Members of
the Compensation, Nomination and Corporate Governance
Committee
- The re-election of the independent proxy and auditors of the
company
Martin Velasco, Chairman of the Board of
Directors, commented, "I would like to thank our shareholders
for their continued trust and support. We are executing a clear
strategy to create long-term value and mitigate risk, and over the
past year have significantly strengthened our team of world-class
life science professionals. A strong focus is our growing
investment in and leveraging of our unique platforms to accelerate
the development of neuro-orphan therapies and the discovery of
neuroinflammation drug candidates."
More information on the Annual General Meeting
is available on the Company's website under the section
investor.
About AC ImmuneAC Immune is a clinical stage
Swiss-based biopharmaceutical company focused on neurodegenerative
diseases with four product candidates in clinical trials. The
Company designs, discovers and develops therapeutic and diagnostic
products intended to prevent and modify diseases caused by
misfolding proteins. AC Immune's two proprietary technology
platforms create antibodies, small molecules and vaccines designed
to address a broad spectrum of neurodegenerative indications, such
as Alzheimer's disease. The Company's pipeline features seven
therapeutic and three diagnostic product candidates. The most
advanced of these is crenezumab, an anti-Abeta antibody in phase 3
clinical studies that is being advanced by the collaboration
partner Genentech, Inc., a wholly owned subsidiary of Roche. Other
business partners include Biogen, Janssen Pharmaceuticals, Nestlé
Institute of Health Sciences, Piramal Imaging and Essex
Bio-Technology.
Forward looking statementsThis press
release contains statements that constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements are statements other than historical
fact and may include statements that address future operating,
financial or business performance or AC Immune's strategies or
expectations. In some cases, you can identify these statements by
forward-looking words such as "may," "might," "will," "should,"
"expects," "plans," "anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "outlook" or "continue," and
other comparable terminology. Forward-looking statements are based
on management's current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include those described under the captions "Item 3.
Key Information-Risk Factors" and "Item 5. Operating and Financial
Review and Prospects" in AC Immune's Annual Report on Form 20-F and
other filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made,
and AC Immune does not undertake any obligation to update them in
light of new information, future developments or otherwise, except
as may be required under applicable law. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
For further information please
contact:
Prof. Andrea PfeiferChief Executive OfficerPhone: +41-21-345 91
21E-mail:andrea.pfeifer@acimmune.com |
Eva SchierCorporate Communications ManagerPhone: +41-21-345 91
34Mobile: +41 79 926 66 03E-mail: eva.schier@acimmune.com
|
Nick Miles/ Toomas Kull Cabinet Privé de Conseils s.a.Phone :
+41 22 552 46 46E-mail : miles@cpc-pr.com
kull@cpc-pr.com |
In the USTed AgneThe Communications Strategy Group
Inc.Phone: +1 781 631 3117E-mail: edagne@comstratgroup.com
|
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/071f6f90-dcaa-4256-8135-9ee61fb01c35
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Aug 2024 to Sep 2024
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Sep 2023 to Sep 2024